Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

By afschroeder • September 18, 2025

Conforti F, Merlo F, Pala L, Canzian J, Tinterri B, De Pas T, Locatelli M, Dickerson JC, Cortes J, Slamon DJ, Gelber R, Bagnardi V. Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence. J Clin Oncol. 2025 Sep 17:JCO2501148. doi: 10.1200/JCO-25-01148. Epub ahead of print. PMID: 40961402.

Tags: Hematology/Oncology, Publications

Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial

Henneghan A, Wertheimer J, Kim S, Gresham G, Shirazipour CH, Jones B, Asher A. Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic[...]

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia

Jang J, Nold T, Marshalek JP, Matthiesen J, Tomassetti S. Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. J Oncol[...]

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition

Schlaak M, Cimminiello C, Pigozzo J, Lee J, Grabbe S, Rutkowski P, Mackiewicz J, Tsai KK, Ascierto PA, Mandalà M, Carnevale-Schianca F, Haferkamp S, Atkinson[...]